High Growth Tech Stocks To Watch In US August 2025
TaskUs, Inc. Class A TASK | 6.94 6.94 | +1.02% 0.00% Post |
In August 2025, the United States stock market has been experiencing a mixed performance, with major indices like the Dow Jones Industrial Average and S&P 500 retreating slightly from record highs due to a pullback in tech stocks. Despite this volatility, high growth tech stocks remain an area of interest for investors seeking opportunities in sectors driven by innovation and robust demand dynamics.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ADMA Biologics | 20.60% | 23.25% | ★★★★★☆ |
| Palantir Technologies | 25.17% | 31.57% | ★★★★★★ |
| Workday | 11.51% | 29.07% | ★★★★★☆ |
| Circle Internet Group | 27.36% | 78.79% | ★★★★★☆ |
| OS Therapies | 57.14% | 70.11% | ★★★★★☆ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| Monopar Therapeutics | 76.01% | 54.38% | ★★★★★☆ |
| Gorilla Technology Group | 27.68% | 129.58% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Aldeyra Therapeutics | 42.88% | 74.81% | ★★★★★☆ |
Here's a peek at a few of the choices from the screener.
Aldeyra Therapeutics (ALDX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market capitalization of $350.39 million.
Operations: Aldeyra Therapeutics focuses on developing therapies for immune-mediated and metabolic diseases. The company's market capitalization stands at $350.39 million, highlighting its position within the biotechnology sector.
Aldeyra Therapeutics, despite its current unprofitability, is poised for significant growth with an expected annual profit increase of 74.8% and revenue growth forecast at 42.9% per year, outpacing the US market average of 9.4%. Recent strategic moves include receiving EMA Orphan Designation for ADX-2191 to treat rare lymphomas and FDA Fast Track Designation for retinitis pigmentosa treatments, underscoring its focus on addressing unmet medical needs in ophthalmology. The company's innovative approach in drug development aims to optimize multiple pathways while minimizing toxicity, setting a solid foundation for future profitability and industry impact.
TaskUs (TASK)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: TaskUs, Inc. is a company that offers outsourced digital services globally, including in the Philippines, the United States, and India, with a market cap of $1.56 billion.
Operations: The company generates revenue primarily through its direct marketing segment, which accounts for $1.10 billion. TaskUs operates in multiple countries, focusing on providing outsourced digital services to a global clientele.
TaskUs has demonstrated robust financial performance, with a notable 24.6% growth in earnings over the past year, outstripping the Professional Services industry's average of 11.3%. This growth trajectory is supported by an expected annual revenue increase of 11.5%, which surpasses the broader U.S market expectation of 9.4%. Additionally, TaskUs has strategically enhanced shareholder value through a recent buyback program where it repurchased shares worth $188.07 million, reflecting confidence in its operational stability and future prospects despite facing legal challenges that are poised for settlement later this year.
Olo (OLO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Olo Inc. provides an open SaaS platform tailored for the restaurant industry in the United States, with a market capitalization of approximately $1.73 billion.
Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $314.33 million.
Despite recent unprofitability, Olo stands out with a projected annual revenue growth of 15.6%, significantly surpassing the US market forecast of 9.4%. This growth is supported by an anticipated earnings increase of 130.64% per year, positioning Olo for potential profitability within three years. The company's focus on innovative software solutions is evident from its R&D investments, which are crucial for maintaining competitive edge in the fast-evolving tech landscape. Recent developments include a significant acquisition by Thoma Bravo for approximately $1.9 billion, underscoring confidence in Olo's strategic value and future prospects in digital ordering systems.
Key Takeaways
- Click this link to deep-dive into the 68 companies within our US High Growth Tech and AI Stocks screener.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
